529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

• Rebecca Kristeleit,
• Howard Burris,
• Kristen Spencer,
• Sarina Piha-Paul,
• Hans Prenen,
• Tara Mitchell,
• David Pinato,
• Solmaz Sahebjam,
• Donna Graham,
• Nuria Kotecki,
• Eric Van Cutsem,
• Brant Delafontaine,
• Thomas Karasic,
• Jeannie Daniel,
• Kevin O’Hayer,
• Ryan Geschwindt

Affiliations

Rebecca Kristeleit

2 Gynaecological Oncology, University College London Hospitals NHS Foundation Trust, London, UK

Howard Burris

2SCRI, Nashville, TN, USA

Kristen Spencer

Aff2 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street 08901 New Brunswick NJ USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Hans Prenen

Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium

Tara Mitchell

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

David Pinato

3Imperial College London, London, UK

Solmaz Sahebjam

Department of Neuro-oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Donna Graham

The Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK

Nuria Kotecki

7Institut Jules Bordet, Brussels, Belgium

Eric Van Cutsem

1University of Leuven, Leuven, Belgium

Brant Delafontaine

3Ghent University Hospital, Ghent, Belgium

Thomas Karasic

5University of Pennsylvania, Philadelphia, PA, USA

Jeannie Daniel

12Incyte Corporation, Wilmington, DE, USA

Kevin O’Hayer

12Incyte Corporation, Wilmington, DE, USA

Ryan Geschwindt

12Incyte Corporation, Wilmington, DE, USA